Hims & Hers Health reported Q1 2026 revenue of $608.1 million, up 4% year-over-year but missing estimates, with a surprise net loss of $92.1 million due to higher costs from shifting to branded GLP-1 (glucagon-like peptide-1) weight-loss drugs. Shares dropped over 14% post-earnings amid margin pressure, though the company raised full-year 2026 revenue guidance to $2.8–$3.0 billion.

Shares of HROW are plunging approximately 21.00% on Tuesday, May 12, 2026, falling from a Monday, May 11 close of $38.04 to approximately $30.05 — a severe earnings-driven selloff following Q1 2026 results released after Monday's close that delivered a deeply missed adjusted EPS of -$0.74 against a -$0.39 consensus estimate (a 90% miss),

HIMS shares are down approximately 15.15% in premarket trading on Tuesday, May 12, 2026, falling from Monday's closing price of $29.14 to around $24.73. The primary catalyst is a significant Q1 2026 earnings miss: the company reported an EPS loss of -$0.40, compared to the analyst consensus estimate of +$0.04 — swinging from a profit of $0.20 per share in Q1 2025.

Takeda to report FY2025 Q4 and full-year results on May 13, 2026, before U. S.

Analysts expect Q4 FY26 revenue of approximately $887 million, a potential decline due to softer U. S.

Analysts expect Q1 2026 revenue of approximately $617 million, up 5% from $586 million in Q1 2025. Consensus EPS estimate stands at $0.03, reflecting a sharp decline from $0.20 in the year-ago quarter amid higher costs.

ZTS shares plunged approximately 13.81% in premarket trading on May 7, 2026, falling from a prior close of $111.22 to around $95.86. The primary catalyst was a disappointing Q1 2026 earnings report released before the market open, with both revenue and adjusted EPS missing Wall Street consensus estimates.

TEVA stock surged approximately +20% over the past 30 days, driven primarily by strong Q1 2026 earnings that beat estimates and robust growth in branded drugs like AUSTEDO. The stock experienced volatility over the past quarter, ending roughly flat with a +3% gain amid broader market pressures and generics challenges, offset by innovative portfolio momentum.

Aurora Cannabis shares have shown volatility in recent weeks, trading near the lower end of their 52-week range amid broader sector pressures. Strategic acquisition of Safari Flower Company bolsters EU Good Manufacturing Practice (GMP) capacity for high-margin international medical sales.

CRDL stock surged +39% over the past 30 days, driven by positive Phase II ARCHER trial results publication and strong earnings beat. Over the past quarter, shares rose +34%, supported by Phase III MAVERIC trial enrollment milestones and $31 million in financing.

Teva Pharmaceutical Industries (TEVA), a global leader in generic and innovative medicines, does not pay a dividend. The company suspended dividends in December 2017 amid efforts to strengthen its balance sheet following high debt from past acquisitions. Prior to suspension, TEVA offered quarterly payments, with the last at $0.09 per share (ex-date November 27, 2017). Current dividend yield stands at 0%, and there is no forward dividend or scheduled ex-dividend date. This positions TEVA outside traditional dividend categories like high-yield or growth stocks, focusing instead on reinvestment for operational turnaround. From what I see, investors seeking immediate income should look elsewhere, but TEVA's robust cash generation signals potential for future policy shifts.

As Teva Pharmaceutical Industries (TEVA), a global leader in generic and innovative medicines, prepares to report first-quarter 2026 earnings on April 29, followed by a conference call at 8:00 a.m. ET, I'm paying close attention. This will be the first major update since full-year 2025 results, which delivered $17.3 billion in revenues, up 4% year-over-year, largely thanks to innovative products like AUSTEDO surpassing $2 billion annually. Investors like us will want to see clear progress on the "Pivot to Growth" strategy, especially as generics face headwinds, including a $1.1 billion impact from Revlimid in 2026. From what I see, shares have climbed significantly on prior beats—such as the +46% EPS surprise in Q4 2025—so this report could either reinforce momentum or highlight risks from pricing pressures and divestitures like the Japan operations.

I've been tracking TEVA, the stock of Teva Pharmaceutical Industries, as it builds a multi-year up-channel after reversing from a prolonged bottom. From what I see on the daily chart, the structure remains solidly bullish, with price having broken decisively above the 200-day moving average. Shorter-term, it holds an uptrend, positioned above most simple and exponential moving averages, such as the MA20 at $29.95 and MA50 at $29.52. A recent pullback has it testing dynamic support near the 20-day MA, which aligns with channel lows noted in trader analyses on platforms like TradingView. One thing that stands out is the declining volume during this consolidation, which often builds pressure for the next upward leg.

In recent trading, Teva Pharmaceutical Industries (TEVA) stock has held firm near the top of its 52-week range, drawing investor attention to its growing biosimilars portfolio. From what I see, the shares have gained from solid results in branded products such as AUSTEDO and AJOVY, along with key regulatory steps that highlight the company's shift to higher-margin innovative therapies. Macroeconomic pressures continue to weigh on generics, but Teva's emphasis on complex generics and biosimilars has kept the price steady, building confidence in its turnaround story through this market cycle.

ASRT stock surged +66% over the past 30 days, driven by strong Q4 2025 earnings beat and optimistic 2026 guidance highlighting Rolvedon growth. Over the past quarter, the stock rose +117%, fueled by improving gross margins, stable product demand, and analyst price target increases.

United Therapeutics Corporation focuses on biotechnology innovations for chronic and life-threatening conditions, particularly in pulmonary diseases. The company's portfolio centers on treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), featuring products like Tyvaso (treprostinil inhalation solution), Orenitram (oral treprostinil), Remodulin, and Adcirca.

Shares of United Therapeutics (UTHR) are surging approximately +17% in premarket trading on Monday, March 30, 2026, with the market not yet open. The primary catalyst is a landmark Phase 3 clinical trial announcement: the TETON-1 pivotal study of nebulized Tyvaso® (treprostinil) met its primary endpoint for treating idiopathic pulmonary fibrosis (IPF), exceeding the already impressive treatment effects seen in the previously completed TETON-2 study.

Shares of Regencell Bioscience Holdings (RGC) are up approximately +16% intraday on March 18, 2026, trading at $26.56 against a prior close of $22.97. No single company-specific press release is driving today's move; the rally is primarily fueled by retail-driven momentum and short squeeze mechanics.

HIMS shares surged approximately +43.85% in premarket trading on Monday, March 9, 2026, rising from a prior close of $15.74 to around $22.80. Primary catalyst: Novo Nordisk officially ended its patent infringement lawsuit against Hims & Hers and announced a landmark partnership to distribute branded Wegovy through the Hims platform at $599/month.

Regencell Bioscience Holdings (RGC) has emerged as one of the most electrifying stories in the stock market in 2025, captivating traders and investors with its staggering price movements.